Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455248 | 0.79 | POLB (0.73) | PIM1POLBGSK3AGSK3BKCNN4 | |
| SCHEMBL5461421 | 0.77 | KCNN4 (0.65) | POLBGSK3AGSK3BKCNN4ALDH1A1 | |
| SCHEMBL3278069 | 0.76 | POLB (0.56) | PIM1POLBGSK3AGSK3BKCNN4 | |
| SCHEMBL19423658 | 0.70 | MAOA (0.46) | ALDH1A1 | |
| SCHEMBL28677873 | 0.69 | SMN1; SMN2 (0.42) | KCNN4ALDH1A1GAASLC5A1SLC5A2 | |
| SCHEMBL5464665 | 0.69 | POLB (0.55) | PIM1POLBGSK3AGSK3BKCNN4 | |
| SCHEMBL22365226 | 0.69 | KDM4E (0.56) | POLBALDH1A1GAA | |
| SCHEMBL8883258 | 0.69 | CES2 (0.47) | — | |
| SCHEMBL6738879 | 0.69 | GSK3A (0.58) | PIM1POLBGSK3AGSK3BALDH1A1 | |
| SCHEMBL30990560 | 0.68 | PIM1 (1.00) | PIM1POLBGSK3AGSK3BHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | PIM1 1268/4885POLB 3236/4885GSK3A 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.